TrimRX
US$ 28.50
retatrutide phase 2 results 2024 2025 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care The MariTide phase 2 trial
Description
What are the research priorities for idiopathic intracranial hypertension
Are there differences in real-world vs
Who is a Good Candidate for GLP-1 Agonist Weight Loss
DOI: 10.1002/ejhf.657 [Google Scholar] Xie S, Zhang M, Shi W, Xing Y, Huang Y, Fang WX, et al
Int J Obes (Lond) 2010
